Result of AGM

Report this content

11 April 2024 1730 BST

Results of Annual General Meeting held on 11 April 2024

AstraZeneca PLC announced the results of the voting at its Annual General Meeting (AGM) today. As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 11 - 14 were passed as special resolutions; all other resolutions were passed as ordinary resolutions.

Resolution Votes for % of votes cast Votes against % of votes cast Votes cast in total Total votes cast as a % of issued share capital Votes withheld
1 To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2023 1,205,690,871 99.88 1,470,816 0.12 1,207,161,687 77.87% 9,700,968
2 To confirm dividends 1,215,177,590 99.94 790,189 0.06 1,215,967,779 78.44% 894,978
3 To reappoint PricewaterhouseCoopers LLP as Auditor 1,208,377,872 99.36 7,843,545 0.64 1,216,221,417 78.45% 642,048
4 To authorise the Directors to agree the remuneration of the Auditor 1,215,717,786 99.98 279,816 0.02 1,215,997,602 78.44% 722,222
5a To re-elect Michel Demaré as a Director 1,197,325,871 98.49 18,416,788 1.51 1,215,742,659 78.42% 1,120,559
5b To re-elect Pascal Soriot as a Director 1,206,729,787 99.26 9,036,742 0.74 1,215,766,529 78.42% 1,098,706
5c To re-elect Aradhana Sarin as a Director 1,212,225,383 99.71 3,509,122 0.29 1,215,734,505 78.42% 1,129,532
5d To re-elect Philip Broadley as a Director 1,197,937,103 98.54 17,773,671 1.46 1,215,710,774 78.42% 1,153,360
5e To re-elect Euan Ashley as a Director 1,213,332,278 99.80 2,375,199 0.20 1,215,707,477 78.42% 1,156,567
5f To re-elect Deborah DiSanzo as a Director 1,215,396,504 99.97 318,525 0.03 1,215,715,029 78.42% 1,149,106
5g To re-elect Diana Layfield as a Director 1,215,424,019 99.98 292,514 0.02 1,215,716,533 78.42% 1,147,602
5h To elect Anna Manz as a Director 1,215,297,866 99.97 417,067 0.03 1,215,714,933 78.42% 1,149,091
5i To re-elect Sheri McCoy as a Director 1,158,846,767 95.32 56,874,293 4.68 1,215,721,060 78.42% 1,142,920
5j To re-elect Tony Mok as a Director 1,215,346,936 99.97 346,157 0.03 1,215,693,093 78.42% 1,170,931
5k To re-elect Nazneen Rahman as a Director 1,191,449,316 98.59 16,988,178 1.41 1,208,437,494 77.95% 8,426,242
5l To re-elect Andreas Rummelt as a Director 1,215,395,253 99.97 314,359 0.03 1,215,709,612 78.42% 1,154,412
5m To re-elect Marcus Wallenberg as a Director 947,479,100 77.93 268,252,536 22.07 1,215,731,636 78.42% 1,132,416
6 To approve the Annual Report on Remuneration for the year ended 31 December 2023 1,158,470,360 95.32 56,835,406 4.68 1,215,305,766 78.40% 1,558,941
7 To approve the Directors' Remuneration Policy 761,702,826 64.43 420,514,520 35.57 1,182,217,346 76.26% 34,645,873
8 To approve amendments to the AstraZeneca Performance Share Plan 2020 769,577,451 65.34 408,204,003 34.66 1,177,781,454 75.97% 39,083,170
9 To authorise limited political donations 1,184,223,861 98.00 24,219,787 2.00 1,208,443,648 77.95% 8,278,265
10 To authorise the Directors to allot shares 1,129,625,915 92.94 85,836,406 7.06 1,215,462,321 78.41% 1,259,562
11 To authorise the Directors to disapply pre-emption rights 1,044,559,011 85.95 170,708,848 14.05 1,215,267,859 78.39% 1,454,048
12 To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments 997,629,834 82.33 214,143,713 17.67 1,211,773,547 78.17% 4,948,031
13 To authorise the Company to purchase its own shares 1,205,828,976 99.23 9,306,860 0.77 1,215,135,836 78.38% 1,585,923
14 To reduce the notice period for general meetings 1,131,157,449 93.07 84,269,754 6.93 1,215,427,203 78.40% 1,294,801

A copy of the resolutions passed at the AGM (other than resolutions concerning ordinary business) has been submitted to the National Storage Mechanism for publication, and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

 Statement in connection with resolutions 5m, 7 and 8

AstraZeneca is pleased that all resolutions were supported at today's Annual General Meeting. In particular, the Board thanks the majority of our shareholders who have supported the Remuneration Policy (the Policy) and will continue to engage with our shareholders and the proxy advisors to explain our need for global benchmarks and pay for performance, which is driven by the Policy.

We will publish an update on the engagement with shareholders on resolutions 5m, 7 and 8 and on any action taken as a result within six months of today's AGM, in accordance with the UK Corporate Governance Code.

Issued capital

As at 9 April 2024, the number of issued shares of the Company was 1,550,231,084 ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against all of the resolutions at the AGM. In accordance with the Company's Articles of Association, on a poll every member present in person or by proxy has one vote for every share held.

AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca.

Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Adrian Kemp
Company Secretary

AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Subscribe

Documents & Links